Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;111(4):835-839.
doi: 10.1002/cpt.2544. Epub 2022 Mar 2.

Neurodegenerative Diseases: The Value of Early Predictive End Points

Sarah Janicki Hsieh  1 , Zoi Alexopoulou  1 , Nitin Mehrotra  1   2 , Arie Struyk  1 , S Aubrey Stoch  1
Affiliations
Review

Neurodegenerative Diseases: The Value of Early Predictive End Points

Sarah Janicki Hsieh et al. Clin Pharmacol Ther. 2022 Apr.

Abstract

Use of early predictive biomarkers of neurodegenerative disease in phase I clinical trials may improve the translation of novel drug therapies from preclinical development through late-stage studies. This article provides a categorical summary of promising biomarker approaches or clinical end points in molecular, cellular, metabolic, electrophysiological, or clinical function that can be used to predict or quantify the progression of neurodegenerative disorders and guide program support.

PubMed Disclaimer

References

    1. Bos, I. et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum. Alzheimers Dement. 15, 644-654 (2019).
    1. Mattsson, N., Cullen, N.C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791-799 (2019).
    1. Lorio, S., Sambataro, F., Bertolino, A., Draganski, B. & Dukart, J. The combination of DAT-SPECT, structural and diffusion MRI predicts clinical progression in Parkinson’s disease. Front. Aging Neurosci. 11, 57 (2019).
    1. Marek, K. et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5, 1460-1477 (2018).
    1. Iaccarino, L. et al. A cross validation of FDG- and amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer’s disease in a clinical setting. J. Alzheimers Dis. 59, 603-614 (2017).

Publication types

MeSH terms

LinkOut - more resources